Registry for individuals interested in inherited cancer predisposition

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Inherited CAncer REgistry (ICARE) Initiative aims to enroll individuals who are interested in participating in studies related to inherited cancer predisposition. This observational registry collects data for various studies, including gene-specific research, and provides educational resources to participants and healthcare providers. Participants receive newsletters with updates on cancer genetics and can engage in monthly web-based case conferences led by experts in the field. The initiative fosters a collaborative environment for research and education in cancer genetics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* At least 18 years of age
* Able and willing to provide informed consent

Where it's running

• Vanderbilt-Ingram Cancer Center
  Nashville, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Tuya Pal, MD — Vanderbilt University Medical Center
• Study coordinator: Anne Weidner, MPH
• Email: ICARE@vumc.org
• Phone: 615-875-2444

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cemiplimab with Quad Shot Radiation for Head and Neck Cutaneous Squamous Cell Carcinoma

  This study tests whether giving cemiplimab together with a short course of Quad Shot radiation can be safely delivered in several rounds to elderly or frail patients with head and neck skin cancer.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · St Louis, Missouri · NCT07869823

• Intrathecal Cytarabine and Hydrocortisone to Treat ICANS in NHL Patients Receiving CAR-T

  This trial tests whether giving cytarabine and hydrocortisone into the spine early after CAR-T therapy can reduce brain-related side effects in adults with non-Hodgkin lymphoma.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07763210

• Casdatifan for refractory metastatic clear cell kidney cancer

  This pilot, first-in-human study tests whether taking casdatifan by mouth can help people with metastatic clear cell renal cell carcinoma that has not responded to prior therapies.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07748988

• Targeted dual-imaging helper for head and neck cancer surgery

  This study tests whether using two imaging agents during surgery can help doctors see tumors and cancerous lymph nodes in adults with head and neck squamous cell carcinoma.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741643

• Intratumoral fluorescent nivolumab before surgery in head and neck cancer

  This study tests injecting fluorescently labeled nivolumab directly into head and neck tumors to see if it is safe and whether it reaches nearby lymph nodes before surgical removal.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741565

• Nemtabrutinib Plus Brexucabtagene Autoleucel (Brexu-Cel) in Relapsed or Refractory Mantle Cell Lymphoma

  This phase 2 trial tests whether adding nemtabrutinib to brexu-cel can help people whose mantle cell lymphoma has come back or not responded to prior treatment.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07673367

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.